Nadja Scherbakov

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Wolfram Doehner

Charité - Universitätsmedizin Berlin

Stephan von Haehling

Universitätsmedizin Göttingen

Anja Sandek

Universitätsmedizin Göttingen

Stefan D. Anker

Charité - Universitätsmedizin Berlin

Nicole Ebner

Universitätsmedizin Göttingen

Miroslava Valentová

University of Göttingen

Carmen Scheibenbogen

Charité - Universitätsmedizin Berlin

Helma Freitag

Humboldt-Universität zu Berlin

Patricia Grabowski

Charité - Universitätsmedizin Berlin

Ewa A. Jankowska

Wroclaw Medical University

Cooperative Institutions

Charité - Universitätsmedizin Berlin

135

Humboldt-Universität zu Berlin

Freie Universität Berlin

Berlin Institute of Health at Charité - Universitätsmedizin Berlin

German Centre for Cardiovascular Research

Heidelberg University

Universität Hamburg

University Medical Center Hamburg-Eppendorf

Klinik und Poliklinik für Neurologie

Innsbruck Medical University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Parallelen in den metabolischen Charakteristika und der Endothelfunktion bei Patienten mit akutem Schlaganfall und Patienten mit chronischer Herzinsuffizienz

Nadja Scherbakov

10.17169/refubium-9093

Cite

Citations (0)

TRPC channels and diacylglycerol dependent calcium signaling in rat sensory neurons

Histochemistry and Cell Biology (2008)

Michaela Kress Johannes Karasek Antonio Ferrer‐Montiel Nadja Scherbakov Rainer Haberberger

TRPC5

Calcium Signaling

10.1007/s00418-008-0477-9

Cite

Citations (44)

Table of Contents

Journal of the American Medical Directors Association (2015)

John Morley Aung Zaw Win Ruth E. Hubbard Iain Lang Nadja Scherbakov

Table (database)

10.1016/s1525-8610(15)00189-9

Cite

Citations (0)

Catabolic Signaling and Muscle Wasting After Acute Ischemic Stroke in Mice

Stroke (2014)

Jochen Springer Susanne Schust Katrin Peske Anika Tschirner André Rex

Background and Purpose— Muscle wasting is a common complication accompanying stroke. Although it is known to impair poststroke recovery, the mechanisms of subacute catabolism after stroke have not been investigated in detail. The aim of this study is to investigate mechanisms of local and systemic catabolism and muscle wasting (sarcopenia) in a model of ischemic stroke systematically. Methods— Changes in body composition and catabolic activation in muscle tissue were studied in a mouse model of acute cerebral ischemia (temporal occlusion of the middle cerebral artery). Tissue wasting (nuclear magnetic resonance spectroscopy), tissue catabolism (caspases-3 and -6, myostatin), and proteasome activity were assessed. Food intake, activity levels, and energy expenditure were assessed, and putative mechanisms of postischemic wasting were tested with appropriate interventions. Results— Severe weight loss in stroke animals (day 3: weight loss, –21.7%) encompassed wasting of muscle (–12%; skeletal and myocardium) and fat tissue (–27%). Catabolic signaling and proteasome activity were higher in stroke animals in the contralateral and in the ipsilateral leg. Cerebral infarct severity correlated with catabolic activity only in the contralateral leg but not in the ipsilateral leg. Lower energy expenditure in stroke animals together with normal food intake and activity levels suggests compensatory mechanisms to regain weight. Interventions (high caloric feeding, β-receptor blockade, and antibiotic treatment) failed to prevent proteolytic activation and muscle wasting. Conclusions— Catabolic pathways of muscle tissue are activated after stroke. Impaired feeding, sympathetic overactivation, or infection cannot fully explain this catabolic activation. Wasting of the target muscle of the disrupted innervation correlated to severity of brain injury. Our data indicate the presence of a stroke-specific sarcopenia.

Catabolism

Stroke

Myostatin

10.1161/strokeaha.114.006258

Cite

Citations (87)

Longer-term impact of hemiparetic stroke on skeletal muscle metabolism—A pilot study

International Journal of Cardiology (2016)

Jennifer Klaer Anja Mähler Nadja Scherbakov Lars Klug Stephan von Haehling

Stroke

Carbohydrate Metabolism

10.1016/j.ijcard.2016.12.143

Cite

Citations (7)

Evaluation eines neuen Testprotokolls mit MOTOmed® als quantifizierbarer Endpunkt zur Bewertung der funktionellen Kapazität in Schlaganfall-Patienten

Aktuelle Ernährungsmedizin (2016)

Andreas Meyer Nadja Scherbakov M Joebges Wolfram Doehner

Effects of a Protein Optimized Diet Combined with Moderate Resistance Training on the Postoperative Course in Older Patients with Hip Fracture

10.1055/s-0036-1583882

Cite

Citations (0)

Body weight changes and incidence of cachexia after stroke

Journal of Cachexia Sarcopenia and Muscle (2019)

Nadja Scherbakov Charlotte Pietrock Anja Sandek Nicole Ebner Miroslava Valentová

Abstract Background Body weight loss is a frequent complication after stroke, and its adverse effect on clinical outcome has been shown in several clinical trials. The purpose of this prospective longitudinal single‐centre observational study was to investigate dynamical changes of body composition and body weight after ischemic stroke and an association with functional outcome. Methods Sixty‐seven consecutive patients (age 69 ± 11 years, body mass index 27.0 ± 4.1 kg/m 2 , 42% female patient, mean ± SD) with acute ischemic stroke with mild to moderate neurological deficit (National Institute of Health Stroke Scale median 4, ranged 0–12) were analysed in the acute phase (4 ± 2 days) and at 12 months (389 ± 26 days) follow‐up. Body composition was examined by dual energy X‐ray absorptiometry. Cachexia was defined according to the consensus definition by body weight loss ≥5% within 1 year and additional clinical signs. Lean tissue wasting was considered if a ratio of upper and lower limbs lean mass sum to squared height (kg/m 2 ) was ≤5.45 kg/m 2 for female patient and ≤7.25 kg/m 2 for male patient. Results According to the body weight changes after 12 months, 42 (63%) patients had weight gain or stable weight, 11 (16%) patients had moderate weight loss, and 14 (21%) patients became cachectic. A relative decline of 19% of fat tissue and 6.5% of lean tissue was observed in cachectic patients, while no changes of lean tissue were observed in non‐cachectic patients after 12 months. The modified Rankin Scale was 48% higher (2.1 ± 1.6, P < 0.05), Barthel Index was 22% lower (71 ± 39, P < 0.01), and handgrip strength was 34% lower (21.9 ± 13.0, P < 0.05) in cachectic compared to non‐cachectic patients after 12 months. The low physical performance if defined by Barthel Index <60 points was linked to the lean tissue wasting (OR 44.8, P < 0.01), presence of cachexia (OR 20.8, P < 0.01), and low body mass index <25 kg/m 2 (OR 11.5, P < 0.05). After adjustment for cofounders, lean tissue wasting remained independently associated with the low physical performance at 12 months follow‐up (OR 137.9, P < 0.05). Conclusions In this cohort study, every fifth patient with ischemic stroke fulfilled the criteria of cachexia within 12 months after index event. The incidence of cachexia was 21%. Cachectic patients showed the lowest functional and physical capacity.

Stroke

Weight change

10.1002/jcsm.12400

Cite

Citations (41)

Cardiac muscle wasting in individuals with cancer cachexia

ESC Heart Failure (2017)

Anush Barkhudaryan Nadja Scherbakov Jochen Springer Wolfram Doehner

Abstract Aims Cachexia is a severe complication of cancer that adversely affects the course of the disease and is associated with high rates of mortality. Patients with cancer manifest symptoms, such as fatigue, shortness of breath, and impaired exercise tolerance, which are clinical signs of chronic heart failure. The aim of this study was to evaluate cardiac muscle wasting in cancer individuals. Methods and results We retrospectively analysed 177 individuals who died of cancer, including 58 lung, 60 pancreatic, and 59 gastrointestinal (GI) cancers, and 42 cancer‐free controls who died of other, non‐cardiovascular reasons. Cancer cachexia (CC) was defined based on clinical and/or pathological diagnosis, body mass index (BMI) <20.0 kg/m 2 and/or oedema‐free body weight loss of 5.0% during the previous year or less. The pathology reports were analysed for BMI, heart weight (HW), and left and right ventricular wall thicknesses (LVWT and RVWT, respectively). The analysis of clinical data included recording of biochemical parameters and medication data of study patients. CC was detected in 54 (30.5%) subjects. Individuals with CC had a significantly lower HW than non‐cachectic subjects (363.1 ± 86.2 vs. 447.0 ± 128.9 g, P < 0.001) and control group (412.9 ± 75.8 g, P < 0.05). BMI correlated with HW in cases with GI cancer ( r = 0.44, P < 0.001), lung cancer ( r = 0.53, P < 0.0001), and pancreatic cancer ( r = 0.39, P < 0.01). Conclusions Body weight loss in individuals with lung, pancreatic, and GI cancers is accompanied by a decrease in HW. In patients with CC who receive cancer treatment, screening for cardiac muscle wasting may have clinical importance.

10.1002/ehf2.12184

Cite

Citations (93)

How to Determine a Metabolically Healthy Body Composition in Cardiovascular Disease

Journal of the American College of Cardiology (2014)

Nadja Scherbakov Stefan D. Anker Wolfram Doehner

Subclinical infection

Atherosclerotic cardiovascular disease

10.1016/j.jacc.2014.05.063

Cite

Citations (2)

Tolerability and Efficacy of s.c. IgG Self-Treatment in ME/CFS Patients with IgG/IgG Subclass Deficiency: A Proof-of-Concept Study

Journal of Clinical Medicine (2021)

Carmen Scheibenbogen Franziska Sotzny Jelka Hartwig Sandra Bauer Helma Freitag

Background: Chronic fatigue syndrome (ME/CFS) is a complex disease frequently triggered by infections. IgG substitution may have therapeutic effect both by ameliorating susceptibility to infections and due to immunomodulatory effects. Methods: We conducted a proof of concept open trial with s.c. IgG in 17 ME/CFS patients suffering from recurrent infections and mild IgG or IgG subclass deficiency to assess tolerability and efficacy. Patients received s.c. IgG therapy of 0.8 g/kg/month for 12 months with an initial 2 months dose escalation phase of 0.2 g and 0.4 g/kg/month. Results: Primary outcome was improvement of fatigue assessed by Chalder Fatigue Scale (CFQ; decrease ≥ 6 points) and of physical functioning assessed by SF-36 (increase ≥ 25 points) at month 12. Of 12 patients receiving treatment per protocol 5 had a clinical response at month 12. Two additional patients had an improvement according to this definition at months 6 and 9. In four patients treatment was ceased due to adverse events and in one patient due to disease worsening. We identified LDH and soluble IL-2 receptor as potential biomarker for response. Conclusion: Our data indicate that self-administered s.c. IgG treatment is feasible and led to clinical improvement in a subset of ME/CFS patients.

Tolerability

Subclass

10.3390/jcm10112420

Cite

Citations (8)